International Clinical Trial: PCSK9 Randomized Evaluation for Contrast-Induced Nephropathy Strategy in Elective PCI (PRECISE-CIN)

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133349) titled 'PCSK9 Randomized Evaluation for Contrast-Induced Nephropathy Strategy in Elective PCI (PRECISE-CIN)' on Sept. 24.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Shanghai Ninth Peoples Hospital,Shanghai JiaoTong University School of Medicine

Condition: Contrast-induced acute kidney injury

Intervention: PCSK9 monoclonal antibody inhibitor group:Administer a subcutaneous injection of Tafolecimab at a single dose of 150 mg within 2 days prior to the scheduled PCI procedure

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-10-01

Target Sample Size: PCSK9 ...